Abstract
The potential cardiac effects of lamotrigine were added to its label late last year, and in March 2021, FDA released a drug safety communication highlighting the increased risk of arrhythmias in patients with heart disease who use lamotrigine. Data from in vitro testing showed that lamotrigine exhibits Class IB antiarrhythmic activity at therapeutically relevant concentrations. In people with structural heart disease or myocardial ischemia, the medication could slow ventricular conduction and increase the risk of arrythmia, the agency warned.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
